VC firm Pivotal closes second $389M therapeutics fund to create companies and back public biotechs

Pivotal bioVenture Partners Fund II has fully closed at $389 million, and the Bay Area firm still has more than 75% of that funding to deploy after a first close during the “peak of the market” in mid-2021, managing general partner Rob Hopfner told Endpoints News.

The fund, unveiled Monday…
Click here to view original post